Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
The approval of the first oncolytic virus for the treatment of metastatic melanoma and the compiling evidence that the use of oncolytic viruses can enhance cancer immunotherapies targeted against various immune checkpoint proteins has attracted great interest in the field of cancer virotherapy. We h...
Saved in:
Main Authors: | Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo |
---|---|
Format: | Artigo |
Language: | English |
Published: |
2018
|
Online Access: | https://doi.org/10.1016/j.ymthe.2018.06.008 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
by: Ylösmäki, Erkko, et al.
Published: (2018) -
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
by: Sara Feola, et al.
Published: (2018) -
Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin
by: Ylösmäki, Erkko, et al.
Published: (2021) -
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy
by: Ylösmäki, Leena, et al.
Published: (2019) -
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
by: Ylösmäki, Erkko, et al.
Published: (2021)